Accurate assessment of axillary lymph node (ALN) status is essential for staging and determining the optimal treatment in breast cancer. In clinically node-negative breast cancer, sentinel lymph node biopsy (SLNB) is the standard procedure for axillary staging, instead of complete axillary lymph node dissection (ALND).(1,2) Patients without SLN metastases do not need to undergo ALND because there is no survival benefit to this procedure.(3,4) Previous guidelines recommend axillary dissection in all patients with metastatic findings on SLNB. Today, even in node-positive patients, the routine use of ALND is being questioned. The 2014 American Society of Clinical Oncology (ASCO) guidelines state that patients with one or two positive nodes undergoing breast conserving surgery and whole breast radiotherapy, who fulfill the Z0011 entry criteria, do not require routine ALND.(3) With changes in practice, the need for more accurate axillary staging is increasing.

The major concern with SLNB is the existence of a false negative rate of 5–10%.(4–6) Skip metastasis of axillary nodes in breast cancer, which has an incidence of about 1.5–19.2%, poses a challenge in relation to the safety of SLNB.(7,8) In cases of skip metastasis, the results obtained via SLNB may be false negative. This potentially increasing false negative rate of SLNB is of concern when positive lymph nodes are not removed.

A number of recent studies have addressed preoperative axillary ultrasound (US) and US-guided fine needle aspiration (US-FNA) as alternative/additional staging procedures to improve the accuracy of SLNB. However, US-FNA resulted in highly variable false negative rates, particularly a lower nodal burden, thus compromising the use of the procedure in the clinical setting.(9-11) Moreover, the correlation between the ALNs identified on US and the SLN identified at surgery has not been fully evaluated. It is not known how often a lymph node visualized and biopsied on axillary US is one of the lymph nodes removed on SLNB. Which lymph node is biopsied under US guidance at presentation is dependent on sonographic visualization. The indication for biopsy is based on size and morphological features identified sonographically.(12) Lymph nodes removed at SLNB are identified by entirely different criteria with use of lymphatic mapping agents, such as radioisotopeand/or blue dye, injected into the breast to identify the draining lymph nodes. In the neoadjuvant setting, a procedure involving marking of the biopsied ALN with metal clips is being adopted. However, there are few reports regarding preoperative marking in operable breast cancer with lower axillary nodal burden.

In the present study, our purpose was to evaluate the efficiency of preoperative US-guided tattooing of ALNs with activated charcoal and to correlate sonographically suspicious lymph nodes with final histologic results through node-to-node analysis. We also aimed todetermine the concordance rate between tattooed lymph nodes and SLNs detected by radioisotope and blue dye.Finally, we proposed the concept of targeted axillary node biopsy with preoperative US-guided tattooing for most accurate axillary staging in patients with breast cancer.

Between January 2014 and February 2017, a total of 125 women with histologically confirmed primary operable breast cancer and one suspicious ALN on preoperative US were deemed eligible for the present study. Patients with multiple lymph node metastasis on preoperative imaging and those undergoing neoadjuvant therapy were excluded. All patients had undergone axillary US before SLNB. Detected lymph nodes were considered suspicious based on any one of the following characteristics: cortical thickness ≥2 mm, eccentric cortical thickening, loss of fatty hilum, diameter of short axis >10 mm, round shape (L/S ratio <1.5).(13-15) In all, 93 patients underwent US-FNA for suspicious nodes prior to surgery.

US-guided tattooing was performed on all lymph nodes with suspicious US characteristics. The procedure was performed preoperatively by injection of 1–3 mL of Charcotrace^TM (activated charcoal 120 mg and sodium chloride in water for injections to 3 mL, Phebra, Lane Cove West, NSW, Australia) into the cortex of the lymph node and the adjacent soft tissue after local anesthesia (Fig. 1). For all SLNB, mapping agents, including radioisotope (technetium-99m phytate) and/or blue dye, were injected before or at the time of surgery. During surgery, the axilla was inspected to determine whether black charcoal tattoo was visible in the node or soft tissue. Lymph nodes identified by a gamma probe or those containing blue dye were regarded as sentinel nodes. All SLNs and tattooed lymph nodes were removed, and the concordance was determined (Fig. 2). Palpable nodes without radioisotope uptake and blue dye were also removed and labeled as non-sentinel nodes.

Each removed lymph node was examined using frozen sections. If a frozen section was positive for metastasis, ALND was performed according to 2014 ASCO guidelines.(3) ALND was omitted in patients with one or two positive nodes undergoing breast-conserving surgery and whole-breast radiotherapy. All tattooed lymph nodes were compared with final histologic results through node-to-node analysis. Each lymph node was finally classified as negative or positive for metastasis. Lymph nodes with micrometastasis were classified as positive for metastasis, and nodes with isolated tumor cells were classified as negative.

The false negative rate was calculated as the number of false negative events divided by the total number of pathological positive nodes. Statistical analysis was performed using SPSS software (ver. 24.0; IBM Corp., Chicago, IL, USA). Confidence intervals (CIs) for false negative rates were calculated using exact Clopper–Pearson confidence limits for the binomial proportion. This study was approved by the Institutional Review Board of Kyungpook National University Chilgok Hospital (KNUCH 2017-02-013), and written informed consent was obtained from each patient before study enrollment.

Clinicopathologic and treatment details of the 125 enrolled patients were described in Table 1. SLNB using both isotope and/or blue dye was successful in all patients. During axillary procedure, all of the tattooed lymph nodes were easily identified by visual inspection and removed in all patients. No significant adverse reactions occurred with charcoal tattooing. A mean of 1.86 (range, 1 to 6) SLN were removed, with 1 SLN in 52 patients, 2 SLNs in 48 patients, and ≥3 SLNs in 25 patients. The mean number of non-sentinel nodes removed was 1.44 (range, 0 to 5). Frozen section examination of SLN revealed that 43 cases (34.4%) had positive results. Of them, 22 cases were performed ALND and the other 21 cases with one or two positive nodes were omitted ALND according to 2014 ASCO guideline.(3) Two patients had negative finding in frozen section, but final pathology showed micrometastasis in that node.

From the tattooed node-based analysis, of the 125 nodes considered as suspicious in US, 43 (34.4%) were positive for metastasis and 82 (65.6%) were negative. 94 (75.2%) patients underwent US-FNA of ALN with suspicious imaging finding. The result was positive in 17 cases (18.1%), negative in 71 cases (75.5%). Six cases (6.4%) showed the results of atypia of undetermined significance. These cases in which FNA findings were indeterminate were analyzed separately by comparing them to final surgical pathologic findings. Regarding the node-to-node analysis, of the US-FNA results, 17 (19.3%) of 88 were true-positive; 58 (65.9%), true-negative; 13 (14.8%), false-negative; zero (0%), false-positive (Fig. 3). False-negative rate of US-FNA was 43.3% (95% CI: 25.6 to 61.1). Sensitivity of US-FNA for sonographically suspicious node was 56.7% (95% CI: 38.9 to 74.4). Negative predictive value was 81.7% (95% CI: 72.7 to 90.1). But, specificity and positive predictive value were 100%. Accuracy of US-FNA for suspicious axillary nodes was 85.2% (95% CI: 77.8 to 92.6). Follow-up of the 6 cases with an indeterminate result in US-FNA revealed that four were lymph node positive as lymph node negative (n = 2). And all these 6 cases matched sentinel nodes.

In final pathology, 45 patients (36.0%) had positive node including two micrometastases. False-negative rate of SLNB was 4.4% (95% CI: 1.6 to 10.5), but there was no skip metastasis. Sensitivity and specificity of SLNB were 95.6% (95% CI: 89.5 to 101.6) and 100% respectively. Negative predictive value was 97.6% (95% CI: 94.2 to 100.9), and positive predictive value was 100%. Accuracy of SLNB was 98.4% (95% CI: 96.2 to 100.6).

In 117 of 125 patients (93.6%), there was concordance between charcoal tattooed ALNs and SLNs. Eight patients (6.4%) had discordance between the tattooed nodes and SLNs. Among the patients with discordance, three patients had metastasis in the tattooed nodes, but also had metastasis in one or two SLNs. The other five patients had no metastasis in either tattooed or sentinel nodes (Table 2).

With changing practice, routine ALND could be omitted in the patients who fulfil Z0011 entry criteria.(3) Therefore the needs for more accurate axillary staging are increasing. SLNB has been proven to be a valid method of assessing ALN status in early breast cancer. However, the major concern with SLNB is the existence of false negative rate of 5 to 10% .(4-6) This potentially increasing false negative rate of SLNB was concerned if the positive lymph node was not excised. And also, the correlation between the ALN identified on preoperative axillary US and the SLN identified at surgery has not been fully evaluated.

In present study, black-tattooed ALNs could be easily detected in all patients during SLNB, fulfilling the technical feasibility of node tattooing without adverse reactions. Intraoperatively, the black pigment from tattooing was well distinguished from blue-stained SLN. Other techniques have been introduced to mark positive lymph nodes, such as metallic markers and radioactive seeds.(2,16,17) Our nodal tattooing technique with activated charcoal is more simple, convenient and cost-effective than other techni-ques. It required no additional imaging to ascertain the location of marker at the time of definitive surgery. Further-more, the tattooing did not interfere with a standard SLNB and allowed for correlation to preoperative-biopsied lymph nodes.

Multiple studies reported the efficacy of US-FNA for preoperative axillary staging in early breast cancer. According to a systematic review reported by Yu et al.(18) the pooled analysis has shown the sensitivity of US-FNA ranged from 40 to 90% and the specificity ranged from 93 to 100%. False-negative rate was approximately 34%. However, those studies could not precisely determine false-negative rate because node-to-node analysis was unavailable. One of the major strength of this study is the direct correlation between the FNA results of suspicious lymph node on US and final pathologic results through performing node-to-node match with US-guided tattooing. The sensitivity and specificity of US-FNA for sonographically suspicious axillary node were 56.7% and 100%, respectively. False-negative rate was 43.3%. The sensitivity and specificity are comparable but false-negative rate is slightly higher than the range of rate (29 to 40%) reported by meta-analysis.(18) This results of preoperative US-FNA, only 19.3% of cases resulted truly positive, with 14.8% being false negative, demonstrated the unsatisfying accuracy of the procedure. In this study, of the 6ALNs with atypia on FNA, 4 ALNs (66.7%) had metastasis in the final pathology. It is questionable whether atypical cell on FNA should be considered positive or negative for metastasis. For that reason, we suggest SLNB with charcoal tattooing in the patients who have ALNs with atypia on cytology. This procedure can be reduced repeated FNA or unnecessary ALNDs.

According to ASCO guidelines for SLNB, six of the trials to date have reported on performance aspects of SLNB. False-negative rate of SLNB reported in the six studies ranged from approximately 4.6% to 16.7%.(3) Three studies reported negative predictive value ranging from 90.1% to 96.1%. Four studies reported overall accuracy of SNB results ranging from 93% to 97.6%. In present study, negative predictive value and accuracy of SLNB was 97.6% and 98.4%, respectively. False-negative rate was 4.4%, but there was no skip metastasis. The failure to identify micrometastases in SLN with frozen biopsy was the cause of these false-negative results.

The correlation between the ALNs identified on US and the SLN identified at surgery has not been fully evaluated. Previous studies have shown that an overlap exists between the SLNs and the suspicious lymph nodes.(19,20) Nathanson (21) reported a correlation between ALNs identified by percutaneous biopsy and ALNs resected at the time of SLNB of 78%. In the present study, most suspicious lymph nodes (117/125, 93.6%) were indeed SLNs. The reason that most of the suspicious ALNs on US were SLNs with a higher concordance rate is unclear. While suspicious lymph nodes on US are identified by their size and morphological features, SLNs are hypothetical lymph nodes or groups of nodes draining a cancer. US and surgical SLN concordance are enhanced when the node is morphologically abnormal. This study, which was not restricted to patients with positive nodes, suggests that in the majority of cases, the nodes resected at SLNB include the node that is identified on US. However, the concordance is not 100 percent and at times, suspicious nodes identified by US is not one of the SLNs. This discordance is concerned if the positive lymph node is not removed. Marking the biopsied axillary node with percutaneous tattooing is helpful to identify previously biopsied node. Selective removal of sonographically suspicious LN as well as SLNs may improve the ability to accurately stage the axilla. Thus, SLNB was easier to conduct, and the possibility of missing a positive lymph node was reduced.

This study was limited to the patients with only one suspicious lymph node on preoperative axillary US. This was because two or more suspicious lymph nodes on US may be expected to be higher burden nodal disease. The patients with higher burden of axillary disease would not fit criteria forinclusion in the Z0011 trial, thereby undergoing ALND. There are other limitations. The determination of suspicious ALNs on US was subjective and potential variability among radiologists can occur. US-FNA is an operator-dependent procedure for obtaining the desired tissue. And of the patients with positive results in frozen section examination of SLN, 21 (49%) cases with one or two positive nodes were omitted ALND. Therefor we cannot entirely rule out the possibility of skip metastasis for the patients who only underwent SLNB. However, we believe that this limitation is inevitable because routine ALND is not currently recommended in breast cancer patients. Also, we think that our method of surgical management for ALNs may not have much effect on our results. This study has single cohort design and small sample size. Thus, to apply with the results in clinical setting, much larger series or randomized control studies will be needed.

In our preliminary study, SLNB in conjunction with US-guided tattooing of sonographically suspicious axillary lymph node is a useful procedure to reduce the false-negative rate of SLNB and to improve the accuracy of intraoperative evaluation of the axillary nodes in patients with early breast cancer. It is expected that preoperative US-FNA can be replaced by US-guided nodal tattooing. So, we proposed the concept of targeted axillary node biopsy with preoperative US-guided tattooing for most accurate axillary staging in patients with early breast cancer.

The authors declare that they have no conflict of interest.